Early Vascular Wall Changes by Magnetic Resonance Imaging (MRI) in Metabolic Syndrome Versus Metabolically Normal Pre-Menopausal Women: A Pilot Study

September 12, 2012 updated by: University of Washington

Early Vascular Wall Changes by MRI in Metabolic Syndrome vs. Metabolically Normal Pre-Menopausal Women: A Pilot Study

The purpose of this study is to compare the vascular permeability of blood vessel walls (of the carotid artery) in pre-menopausal women who have metabolic syndrome (syndrome of having at least 3/5 following features- increased abdominal fat, low good cholesterol (HDL-C), elevated fasting blood fats (triglycerides), elevated blood pressure, an elevated fasting glucose) versus those women who are normal weight and with normal cholesterol, blood fats, blood pressure, and blood sugar. We are using a novel technology to measure vascular permeability known as dynamic contrast enhancement magnetic resonance imaging (DCE-MRI). The primary variable is ktrans ratio which is a mathematically derived quantity obtained from DCE-MRI. We are trying to identify novel markers of early atherosclerosis in young women.

Study Overview

Status

Unknown

Conditions

Detailed Description

This study involves a phone screen & 2 study visits:

  • Screening visit, which includes a quick finger stick cholesterol, glucose, triglycerides test (cholestech) to determine qualification, waist measurement, weight. Results are provided regardless of qualification. If the volunteer qualifies, a full blood draw (approximately 45cc or 3 Tablespoons) will occur. A snack is provided once blood is drawn. Additional study visit procedures include a medical history questionnaire including menstrual history, height & weight measurement, vital signs, and waist & hip measurements. This study lasts up to 90 minutes.
  • MRI visit (to occur within a week of screening visit) occurs once serum pregnancy & creatinine results are received & only if approved to continue by P.I. (e.g. negative serum pregnancy and eGFR>60). An IV catheter is placed in the antecubital vein to administer an injection of (gadolinium) contrast medium. A coil is placed on each side of the subject's neck while laying flat on a bench, with her upper body inside the MRI scanner. The entire MRI procedure takes approximately 60 minutes.

Study Type

Observational

Enrollment (Actual)

43

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Washington
      • Seattle, Washington, United States, 98104
        • Harborview/University of Washington

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

35 years to 50 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

Pre-menopausal Women

Description

Inclusion Criteria:

  • Pre-menopausal women (age 35-50)

    • still having menstrual periods

Exclusion Criteria:

  • History of diabetes mellitus
  • History of cardiovascular disease (peripheral vascular disease, coronary artery disease, cerebrovascular disease)
  • Serum creatinine >1.2 mg/dL (eGFR <60 ml/min.)
  • Active rheumatologic disease
  • Use of hormonal contraception*
  • Pregnant or planning a pregnancy within the next 3 months
  • Fasting triglycerides ≥ 500 mg/dL
  • Fasting LDL-C ≥ 190 mg/dL
  • Currently taking lipid lowering medications*
  • Currently taking vaso-active (blood pressure) medications*
  • Hypertension: SBP ≥ 140 and or DBP ≥90 mm Hg
  • Chronic use of aspirin (prn use is allowed)
  • Chronic use of non-steroidal anti-inflammatory medications (prn use is allowed)
  • Tobacco use within 3 months of starting study
  • Participation in another clinical trial within the last 30 days
  • MRI specific exclusion criteria:

    • History of claustrophobia
    • History of decrease in kidney function (eGFR <60 ml/min.)
    • History of reaction to a contrast medium or dye used for an MRI, CT Scan, or X-ray
    • History of significant anemia or other blood disease
    • History of seizures
    • MRI-incompatible metal such as internal metal hardware or devices * Drugs within the following classifications are exclusionary: Antilipemics, antilipidemics, beta blockers, ACE inhibitors, angiotensin receptor blockers, diuretics, calcium channel blockers, alpha blockers, nitrates, and all hormonal contraceptives

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Women with Metabolic Syndrome

Pre-menopausal women with Metabolic Syndrome

Age 35-50 and any 3 of the following:

Fasting triglycerides ≥ 150 mg/dL, Waist measurement ≥ 35 inches, HDL < 50mg/dL, Fasting glucose ≥ 100mg/dL but <126mg/dL or Blood pressure ≥ 130/85 or taking medication to treat high blood pressure.

Non-Metabolic Syndrome (healthy) women

Non-Metabolic syndrome pre-menopausal women age 35-50

  • Body Mass Index ≤ 25
  • Regular menstrual cycles (occur every 24-35 days)
  • Fasting glucose < 100mg/dL
  • HDL-C ≥ 50mg/dL
  • Waist measurement ≤ 35 inches
  • Fasting triglycerides < 150mg/dL

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
ktrans of the carotid artery wall
Time Frame: baseline
Ktrans is a transfer constant that is a measure of vascular permeability.
baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
carotid artery intima-media thickness as measured by MRI
Time Frame: baseline
Carotid intima-media thickness is a measure of the actual thickness of the intima and media layers of the carotid artery wall.
baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Pathmaja Paramsothy, M.D.,M.S., University of Washington

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2009

Primary Completion (Actual)

July 1, 2012

Study Completion (Anticipated)

July 1, 2013

Study Registration Dates

First Submitted

February 11, 2010

First Submitted That Met QC Criteria

February 12, 2010

First Posted (Estimate)

February 15, 2010

Study Record Updates

Last Update Posted (Estimate)

September 14, 2012

Last Update Submitted That Met QC Criteria

September 12, 2012

Last Verified

September 1, 2012

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Metabolic Syndrome

3
Subscribe